RenovoRx RNXT
NASDAQ RNXT
$1.56 -0.01 (-0.64%)
At close: Sep 30, 2026 · 4:00 PM EDT

RenovoRx (RNXT) EBITDA Margin (2025 - 2026)

Updated

RenovoRx's EBITDA Margin came in at -367.88% for Q2 2026, up 29.75 percentage points from -397.63% a year earlier and up 248.11 percentage points from the prior quarter.

Analysis

RenovoRx (RNXT) EBITDA Margin (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, RenovoRx reported EBITDA Margin of -634.31%; for FY2025, it was -935.89%, up 24575.74 percentage points from FY2024.

  • Going back by year, EBITDA Margin was -25511.63% in FY2024.
  • Business Quant data shows RNXT's EBITDA Margin at -615.99% (Q1 2026), -1479.83% (Q4 2025) and -827.07% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Thermo Fisher Scientific 251.30 Bn 230.45 Bn 4.88 Bn 24.20%
2 Abbott Laboratories 174.70 Bn 145.78 Bn 7.27 Bn 21.86%
3 Danaher 158.94 Bn 142.76 Bn 3.61 Bn 28.51%
4 Intuitive Surgical 145.87 Bn 125.42 Bn 1.96 Bn 41.08%
5 Medtronic 111.49 Bn 77.36 Bn 6.34 Bn 25.55%
6 Stryker 106.96 Bn 93.08 Bn 4.50 Bn 29.67%
7 Boston Scientific 63.62 Bn 58.63 Bn 3.85 Bn 28.17%
8 Edwards Lifesciences 50.80 Bn 34.92 Bn 1.35 Bn 31.93%
9 Becton Dickinson 49.59 Bn 46.74 Bn 2.32 Bn 24.62%
10 RenovoRx 70.84 Mn 70.84 Mn 766,000.00 -367.88%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -367.88%
Mar 31, 2026 -615.99%
Dec 31, 2025 -1,479.83%
Sep 30, 2025 -827.07%
Jun 30, 2025 -397.63%
Mar 31, 2025 -1,578.17%
API Access

RenovoRx EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RNXT&period=max&api_key=YOUR_API_KEY